Wuhan YZY Biopharma Co (HKSE:02496) General and Admin. Expense: HK$11.28 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Wuhan YZY Biopharma Co General and Admin. Expense?

Wuhan YZY Biopharma Co HKSE:02496 General and Admin. Expense is HK$11.28 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Wuhan YZY Biopharma Co's General and Admin. Expense for the six months ended in Dec. 2025 was HK$4.35 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$11.28 Mil.

Wuhan YZY Biopharma Co General and Admin. Expense Related Terms

Wuhan YZY Biopharma Co General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Wuhan YZY Biopharma Co's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co General and Admin. Expense Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
10.18 22.92 12.14 15.36 11.35

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial 8.09 8.10 7.32 6.93 4.35

Wuhan YZY Biopharma Co General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$11.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of HK$11.28 Mil mean?
Wuhan YZY Biopharma Co (HKSE:02496) has a General and Admin. Expense of HK$11.28 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's General and Admin. Expense too high?
Wuhan YZY Biopharma Co's current General and Admin. Expense is HK$11.28 Mil.
How does Wuhan YZY Biopharma Co's General and Admin. Expense compare to VRTX and REGN?
Wuhan YZY Biopharma Co's General and Admin. Expense of HK$11.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current General and Admin. Expense is HK$11.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current General and Admin. Expense of HK$11.28 Mil. The current General and Admin. Expense is HK$11.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current General and Admin. Expense is HK$11.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan YZY Biopharma Co Business Description

Address No. 666 Gaoxin Road, Building C2-1, Optics Valley Bio-City, East Lake High Tech Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.